Publicaciones (79) Publicaciones en las que ha participado algún/a investigador/a

2021

  1. A Web-based Application for Spirometry Quality in a Public Health System. 10 Year Follow Up

    Archivos de Bronconeumologia, Vol. 57, Núm. 11, pp. 724-725

  2. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

    Chest, Vol. 159, Núm. 1, pp. 58-72

  3. Association of the CFTR gene with asthma and airway mucus hypersecretion

    PLoS ONE, Vol. 16, Núm. 6 June

  4. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  5. COVID-19 vaccine prioritisation for people with cystic fibrosis

    Journal of Cystic Fibrosis

  6. Carmustine Pulmonary Toxicity: A Diagnosis to Bear in Mind Even in Times of COVID

    Archivos de Bronconeumologia, Vol. 57, pp. 52-54

  7. Cell-selective altered cargo properties of extracellular vesicles following in vitro exposures to intermittent hypoxia

    International Journal of Molecular Sciences, Vol. 22, Núm. 11

  8. Ceramide metabolism and parkinson’s disease—therapeutic targets

    Biomolecules, Vol. 11, Núm. 7

  9. Ceramide metabolism enzymes—therapeutic targets against cancer

    Medicina (Lithuania), Vol. 57, Núm. 7

  10. Checking Siblings of Patients with Idiopathic Pulmonary Fibrosis as a Scheme for Early Disease Detection

    Annals of the American Thoracic Society

  11. Climate Change: SEPAR's Responsibilities

    Archivos de Bronconeumologia

  12. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  13. Clinical characteristics of SARS-CoV-2 infection in children with cystic fibrosis: An international observational study

    Journal of Cystic Fibrosis, Vol. 20, Núm. 1, pp. 25-30

  14. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 2, pp. 408-416

  15. Completion of treatment for latent TB infection in a low prevalence setting

    International Journal of Tuberculosis and Lung Disease

  16. Concordancia interobservador de la ecocardiografía transtorácica en el seguimiento de la embolia pulmonar

    Revista española de patología torácica, Vol. 33, Núm. 4, pp. 235-237

  17. Correction to: Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study (European Journal of Clinical Microbiology & Infectious Diseases, (2020), 39, 8, (1513-1525), 10.1007/s10096-020-03870-3)

    European Journal of Clinical Microbiology and Infectious Diseases

  18. Correction to: Impact of reducing the duration of antibiotic treatment on the long-term prognosis of community acquired pneumonia (BMC Pulmonary Medicine, (2020), 20, 1, (261), 10.1186/s12890-020-01293-6)

    BMC Pulmonary Medicine

  19. Correction to: REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study (Drugs, (2021), 81, 15, (1763-1774), 10.1007/s40265-021-01597-9)

    Drugs

  20. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial)

    PharmacoEconomics, Vol. 39, Núm. 3, pp. 331-343